Fyodor Biotechnologies

Executive Summary

Fyodor Biotechnologies is a Baltimore-based diagnostics company developing a proprietary, non-invasive urine-based test platform that is as simple to use as a pregnancy test. The test requires no blood and can be administered at home, enabling decentralized diagnosis of infectious diseases. The platform has been validated in collaboration with leading institutions including Johns Hopkins, Duke University, and the University of Lagos, demonstrating high accuracy. The company has secured CE marking and regulatory approvals in Nigeria, Côte d'Ivoire, Kenya, and the Democratic Republic of Congo, positioning it for commercial rollout in high-burden African markets. Fyodor's technology addresses a critical gap in global health diagnostics by offering a low-cost, scalable solution suitable for resource-limited settings. With a founding date of 2015 and initial traction in African regulatory approvals, the company is well-positioned for growth pending additional funding and US market entry. Its products could potentially target diseases such as malaria, typhoid, or other febrile illnesses. Given the validated partnerships and existing approvals, Fyodor represents an opportunistic investment in point-of-care diagnostics with significant social impact and commercial potential. However, as a private company with limited public information, the conviction score is moderate.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Submission for US Market Entry40% success
• Q2 2026Series B Fundraising Round70% success
• Q4 2026Expansion into Additional African Markets (e.g., Ghana, Uganda)80% success